Amylyx publishes phase 2 trial data for Wolfram syndrome treatment

May 15, 2026 12:12 PM

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found